alpha-aminopyridine has been researched along with Endometrial Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Asmus, EJ; Block, MS; Butler, KA; Camoriano, JK; Colon-Otero, G; Copland, JA; Dinh, TA; Foster, NR; Glaser, GE; Hou, X; Jatoi, A; Langstraat, CL; Robertson, MW; Wahner Hendrickson, A; Weroha, SJ; Zanfagnin, V | 1 |
| Bian, X; Cheng, H; Gao, J; Liu, P; Luo, F; Roberts, TM; Rui, C; Wang, D; Wang, Y; Zhao, JJ; Zheng, T | 1 |
| Borger, D; Bradford, LS; Clark, RM; Foster, R; Groeneweg, JW; Growdon, WB; Rauh-Hain, A; Rueda, BR; Zhang, L; Zukerberg, LR | 1 |
| Bull, CO; Cornell-Kennon, S; Eathiraj, S; Iimura, S; Kelleher, EW; Kizer, DE; Koerner, S; Lapierre, JM; Liu, Y; Makhija, S; Matsuda, A; Moussa, M; Namdev, N; Savage, RE; Schwartz, B; Szwaya, J; Vensel, D; Volckova, E; Westlund, N; Wu, H | 1 |
| Arnaud, A; Berton-Rigaud, D; Fabbro, M; Favier, L; Floquet, A; Foa, C; Heudel, PE; Joly, F; Kalbacher, E; Kaminsky, MC; Lesoin, A; Lortholary, A; Meunier, J; Priou, F; Ray-Coquard, I; Roche-Forestier, S; Roemer-Becuwe, C; Selle, F; Tazi, Y; Treilleux, I; You, B | 1 |
| Bonazzi, VF; Cummings, MC; Geng, X; Ju, RJ; Mahon, CE; Packer, LM; Pollock, PM; Stephenson, SA | 1 |
| Abbadessa, G; Eathiraj, S; Hall, T; Schwartz, B; Wick, MJ; Yu, Y | 1 |
2 trial(s) available for alpha-aminopyridine and Endometrial Neoplasms
| Article | Year |
|---|---|
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Purines; Receptors, Estrogen | 2020 |
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease Progression; Endometrial Neoplasms; Female; Humans; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Recurrence; Treatment Outcome | 2017 |
5 other study(ies) available for alpha-aminopyridine and Endometrial Neoplasms
| Article | Year |
|---|---|
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Humans; Mice; Mice, Transgenic; Morpholines; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Recombinational DNA Repair; Spheroids, Cellular | 2018 |
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Class I Phosphatidylinositol 3-Kinases; Endometrial Neoplasms; Female; Humans; Mice; Mice, SCID; Morpholines; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
Topics: Administration, Oral; Allosteric Regulation; Aminopyridines; Animals; Antineoplastic Agents; Carcinoma, Endometrioid; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Imidazoles; Mice; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship | 2016 |
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Morpholines; Mutation; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Sulfonamides; Thiazoles; Xenograft Model Antitumor Assays | 2017 |
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Topics: Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Fibroblast Growth Factor; Xenograft Model Antitumor Assays | 2017 |